医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells

摘要Non-alcoholic fatty liver disease(NAFLD)is emerging as an epidemic risk factor for hepatocellular carcinoma(HCC).The progression of NAFLD to HCC is closely associated with paracrine communication among hepatic cells.Vascular endothelial growth factor A(VEGFA)plays a key role in NAFLD and HCC;however,the cellular communication of VEGFA in the pathological transition from NAFLD to HCC remains unclear.Here,we found that VEGFA elevation was considerably distributed in hepatocytes of clinical and murine NAFLD-HCC specimens.Notably,progression from NAFLD to HCC was attenuated in hepatocyte-specific deletion of Vegfa(VegfaAhep)mice.Mechanistically,VEGFA activated human hepatic stellate cell(HSC)LX2 into a fibrogenic phenotype via VEGF-VEGFR signaling in fatty acid medium,and HSC activation was largely attenuated in Vegfa△hep mice during NAFLD-HCC progression.Additionally,a positive correlation between VEGFA and hepatic fibrosis was observed in the NAFLD-HCC cohort,but not in the HBV-HCC cohort.Moreover,LX2 cells could be activated by conditioned medium from NAFLD-derived organoids,but not from HBV livers,whereas this activation was blocked by a VEGFA antibody.In summary,our findings reveal that hepatocyte-derived VEGFA contributes to NAFLD-HCC development by activating HSCs and highlight the potential of precisely targeting hepatocytic VEGFA as a promising therapeutic strategy for NAFLD-HCC.

更多
广告
作者 Hao Shen [1] Han Yu [1] Qian-yu Li [2] Ya-ting Wei [3] Jing Fu [1] Hui Dong [1] Dan Cao [1] Lin-na Guo [1] Lei Chen [1] Yuan Yang [4] Ying Xu [1] Meng-chao Wu [1] Hong-yang Wang [3] Yao Chen [1] 学术成果认领
作者单位 International Cooperation Laboratory on Signal Transduction,National Center for Liver Cancer,Ministry of Education Key Laboratory on signaling Regulation and Targeting Therapy of Liver Cancer,Shanghai Key Laboratory of Hepato-biliary Tumor Biology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University/NAVAL Medical University,Shanghai 200433,China [1] Department of Pathology,Shanghai Tenth People's Hospital,Tongji University School of Medicine,Shanghai 200072,China [2] International Cooperation Laboratory on Signal Transduction,National Center for Liver Cancer,Ministry of Education Key Laboratory on signaling Regulation and Targeting Therapy of Liver Cancer,Shanghai Key Laboratory of Hepato-biliary Tumor Biology,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University/NAVAL Medical University,Shanghai 200433,China;Institute of Metabolism and Integrative Biology,Fudan University,Shanghai 200438,China [3] Third Department of Hepatic Surgery,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai 200433,China [4]
栏目名称
发布时间 2022-12-16(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览1
  • 下载0
中国药理学报(英文版)

中国药理学报(英文版)

2022年43卷11期

2917-2928页

SCIMEDLINEISTICCSCDCABP

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷